Haemonetics Co. (NYSE:HAE) Shares Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. grew its stake in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 166.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,011 shares of the medical instruments supplier's stock after acquiring an additional 8,133 shares during the period. Vontobel Holding Ltd.'s holdings in Haemonetics were worth $1,016,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of HAE. Nisa Investment Advisors LLC boosted its position in shares of Haemonetics by 124.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier's stock worth $92,000 after buying an additional 632 shares in the last quarter. KBC Group NV grew its position in shares of Haemonetics by 54.6% in the fourth quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier's stock valued at $157,000 after purchasing an additional 712 shares during the last quarter. iSAM Funds UK Ltd purchased a new position in shares of Haemonetics during the 3rd quarter worth approximately $204,000. CWC Advisors LLC. acquired a new position in shares of Haemonetics during the 3rd quarter worth approximately $231,000. Finally, Versor Investments LP lifted its stake in Haemonetics by 9.1% in the 3rd quarter. Versor Investments LP now owns 3,600 shares of the medical instruments supplier's stock valued at $289,000 after buying an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Trading Down 0.7 %

Shares of HAE stock traded down $0.47 during trading hours on Friday, hitting $62.98. 986,273 shares of the company were exchanged, compared to its average volume of 1,030,576. The firm has a fifty day moving average of $72.61 and a 200 day moving average of $76.66. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 1 year low of $58.80 and a 1 year high of $97.97. The firm has a market cap of $3.16 billion, a PE ratio of 24.79, a PEG ratio of 1.11 and a beta of 0.39.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts' consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. StockNews.com downgraded Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. JPMorgan Chase & Co. initiated coverage on Haemonetics in a research report on Friday, December 6th. They set an "overweight" rating and a $116.00 price objective for the company. JMP Securities reduced their target price on shares of Haemonetics from $125.00 to $100.00 and set a "market outperform" rating on the stock in a report on Friday, February 7th. Needham & Company LLC decreased their price target on shares of Haemonetics from $112.00 to $108.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. Finally, Barrington Research cut their price objective on shares of Haemonetics from $108.00 to $95.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $101.67.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.